Mostafa M.E. Hamza's research while affiliated with Cairo University and other places
What is this page?
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
Publications (5)
Purpose:
To study the safety of extended monthly intravitreal infliximab injections in patients with active posterior uveitis in Behcet's disease (APUBD).
Methods:
This is a prospective, interventional, noncomparative, open-label, pilot study of 9 monthly intravitreal infliximab injections (1mg/0.05ml) for twenty-two eyes of 16 patients with APUB...
Purpose:
To assess the impact of COVID-19 pandemic on ophthalmology practice in Cairo metropolitan area.
Methods:
A cross sectional observational analytic study among ophthalmologists practicing in different hospitals in Cairo metropolitan area. The data was collected through a self-administered questionnaire covering general measures taken duri...
Purpose:
To assess the safety and efficacy of intravitreal infliximab (1 mg/0.05 mL) in patients with refractory posterior uveitis in Behcet's disease.
Methods:
Twenty patients were included in this study. Best corrected visual acuity (BCVA), vitreous haze (graded 0-4), vasculitis, retinitis, and papillopathy (presence or absence) were assessed...
Purpose: To assess the safety and efficacy of intravitreal infliximab (1 mg/0.05 mL) in patients with refractory posterior uveitis in Behcet’s disease. Methods: Twenty patients were included in this study. Best corrected visual acuity (BCVA), vitreous haze (graded 0–4), vasculitis, retinitis, and papillopathy (presence or absence) were assessed at...
Purpose: To assess the safety and efficacy of intravitreal infliximab (1 mg/0.05 mL) in
patients with refractory posterior uveitis in Behcet’s disease. Methods: Twenty patients were included in this study. Best corrected visual acuity (BCVA), vitreous haze (graded 0–4), vasculitis, retinitis, and papillopathy (presence or absence) were assessed at...
Citations
... At 18 weeks of follow-up, they observed statistically significant improvements in mean visual acuity, reductions in mean central macular thickness, and decreased mean vitreous haze scores. In contrast, an open-label study of monthly intravitreal IFX injections reported a high ocular complication rate and failure to control BD uveitis, leading the authors to advice against this approach [38]. Studies have discovered that excessively high IFX concentrations in the vitreous cavity may provoke uveitis because of immune response; therefore, this therapy is recommended as an alternative treatment for patients who cannot tolerate systemic IFX medication [36]. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/722604155498503-1549293664325_Q64/Mohammad-Refaat-2.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/692611421577222-1542142839998_Q64/Abdussalam-Abdullatif.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/1102657552945153-1639905455744_Q64/Tamer-Macky.jpg)
... 5 Importantly, these perceptions have been reflected in the literature. 6,7 In addition, ocular manifestations of the virus, including follicular conjunctivitis, epiphora or chemosis, may indicate the first presentation of COVID-19. 8,9 Similarly, ophthalmic consultations often require several examination techniques involving visual acuity, intraocular pressure measurements, and fundus examinations. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/867972679749632-1583952221159_Q64/Heba-El-Saied.jpg)
... Hamza et al. demonstrated the safety and efficacy of a single 1 mg/0.05 ml intravitreal IFX injection in 20 patients with refractory uveitis due to BD [37]. At 18 weeks of follow-up, they observed statistically significant improvements in mean visual acuity, reductions in mean central macular thickness, and decreased mean vitreous haze scores. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/11431281108931198-1671652334608_Q64/Mohamed-Sidky-2.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/320485013819393-1453420989577_Q64/Gaafar-Ragab.jpg)
